Women's Health

The Pharmacy Times® Women’s Health resource center provides clinical news and articles, pertaining to women’s wellness, nutrition, fitness, weight loss, and answers to other potentially more intimate questions.

What can we help you find?
[[thumbnail_alt_text]]
Women comprise more than 60% of pharmacy graduates, yet gender gaps still exist in pharmacy ownership, school deanships, and other leadership positions.
 
[[thumbnail_alt_text]]
New ruling means up to 126,400 women of childbearing age may need to pay out-of-pocket for birth control. 
 
[[thumbnail_alt_text]]
In addition to finding that depression affects up to 70% of women transitioning into menopause, investigators have also identified the greatest risk factors.
[[thumbnail_alt_text]]
Gardasil 9 approved for the prevention of oropharyngeal cancer and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.
[[thumbnail_alt_text]]
Oriahnn is the first FDA-approved nonsurgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women
[[thumbnail_alt_text]]
The FDA recently announced its approval of a vaginal gel that acts as a method of contraception for women. It is the first non-hormonal, vaginal pH regulator contraceptive to be approved by the FDA.
[[thumbnail_alt_text]]
The authors concluded that costs were significantly higher for women with migraines than men and that costs resulting from migraine treatment increased as the patients got older.
 
[[thumbnail_alt_text]]
Suzanne Soliman, PharmD, BCMAS, Founder and President of Pharmacist Moms, explains why there is a still a need for women to hold positions of leadership in pharmacy, despite the strides in recent years.
[[thumbnail_alt_text]]
Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).
 
[[thumbnail_alt_text]]
The injection’s active ingredient, 17α hydroxyprogesterone caproate (also known as 17P), is currently the only approved treatment for pregnant women who have had a prior spontaneous preterm birth.
[[thumbnail_alt_text]]
Although 62% of the first professional degrees in pharmacy were awarded to women in 2017-2018,1 there are only about half as many female pharmacy owners as there are women graduating from pharmacy school.
[[thumbnail_alt_text]]
The newly approved therapy is equivalent to AstraZeneca Pharmaceuticals’ Faslodex injection, 250mg/5mL.